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Blood-based interferon-gamma (IFN-γ) release assays (IGRAs) have been proven to be
useful in the diagnosis of Mycobacterium tuberculosis (Mtb) infection. However, IGRAs
have not been recommended for clinical practice in most low-income settings due to
cost-intensive limitations and shortage of clinical data available. The established T-SPOT.
TB assay containing Mtb-specific antigens ESAT-6 and CFP10 are widely used for
immunodiagonsis of Mtb infection, but the high cost is one of the restricting factors
against its clinical application in the developing countries. More recently, a cost-saving
IGRA assay, TS-SPOT, was approved in China. This new assay contains an additional
antigen Rv3615c. Rv3615c contains broadly recognized CD4+ and CD8+ epitopes,
and T-cell responses to Rv3615c are as specific for Mtb infection as the responses to
ESAT-6 and CFP10 in bothMtb-infected humans andM. bovis-infected cattle. Therefore,
we assessed the likely effect of inclusion of Rv3615c as stimulus besides ESAT-6 and
CFP10 in an IGRA assay and evaluated the performance of TS-SPOT for diagnosis ofMtb
infection and active TB compared with T-SPOT.TB. We tested 155 active TB patients,
90 non-TB lung disease patients, and 55 healthy individuals. The results presented
an improved positive rate for diagnosis of active TB and Mtb infection, that could be
attributable to inclusion of Rv3615c in the mixture of stimulatory antigens. The diagnostic
efficiency of TS-SPOT assay for active TB was as follows: sensitivity 80.00%, specificity
83.45%, positive predictive value (PPV) 83.78%, negative predictive value (NPV) 83.45%,
positive likelihood ratio (LR+) 4.83, and negative likelihood ratio (LR−) 0.24. The results
were similar to those of T-SPOT.TB, with an excellent agreement (κ = 0.91, 95%
CI: 0.85–0.95) being observed between these two assays. The sensitivities of the
TS-SPOT assay varied for patients with different forms of active TB, with the highest
sensitivity for patients with culture-positive pulmonary TB (92.16%) and the lowest
for those with tuberculosis meningitis (50.00%). Taken together, the current evidence
indicates that this new TS-SPOT assay is a useful adjunct to the current tests for rapid
diagnosis of active TB and Mtb infection in low-income and high-incidence settings due
to its characteristics of cost-effectiveness and high-quality.
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INTRODUCTION
Tuberculosis (TB), the disease caused by Mycobacterium
tuberculosis (Mtb), still remains a major global public health
concern. According to the updated WHO global TB report,
approximately one-third of the world’s populations are infected
asymptomatically with Mtb, and about 5–10% of these people
develop active TB. In 2015, there were an estimated 10.4
million new TB cases and 1.4 million TB deaths worldwide,
and an additional 0.4 million deaths resulting from TB disease
among people co-infected with HIV (WHO, 2016). Although the
number of TB deaths dropped by 22% during the period of 2000–
2015, TB remained one of the top 10 causes of death from any
cause worldwide in 2015 (WHO, 2016). The results of the fifth
Chinese national TB epidemiological survey in 2010 showed that
the TB prevalence was 469/100,000 among population over 15
years old, and 4.99 million active TB cases were estimated across
the country (The Office of the Fifth National TB Epidemiological
Survey, 2012).
In China, diagnosis of TB is usually based on a combination
of regular doctor inquiry, clinical presentation, radiological and
pathological changes, and bacteriological findings of acid-fast
bacilli (AFB). However, the smear microscopy for AFB has a low
sensitivity as only 44% of all new adult cases and 15–20% of
childhood cases are identified by the presence of AFB in sputum
smears (Pai andO’Brien, 2008). The gold standard for the definite
diagnosis of TB is the detection of Mtb by bacterial culture,
which usually takes >1 month to provide a diagnostic end-point
and delays the treatment initiation (Richeldi, 2006). Moreover,
diagnosis and treatment decisions may be difficult in cases with
clinical suspicion of TB and negative AFB sputum smears. Being
rapid and easy to apply, tuberculin skin test (TST) has been used
as an immunodiagnostic tool to support the physician’s decision
process for decades, but it suffers from poor specificity due to
the cross-reaction of non-tuberculosis mycobacteria (NTM) or
Bacillus Calmette-Guerin (BCG) vaccination (Richeldi, 2006),
especially in developing countries with high TB prevalence.
In recent years, blood-based in vitro interferon (IFN)-γ release
assays (IGRAs) have been developed as alternatives to TST
for the rapid immunodiagnosis of Mtb infection. Both TST
and IGRAs detect the presence of persistent Mtb-specific T-cell
responses and represent indirect markers for past or present
infection (Young et al., 2009). IGRAs measure IFN-γ secretion
after in vitro stimulation of whole blood or peripheral blood
mononuclear cells (PBMCs) with antigens (ESAT-6 and CFP10).
These antigens are encoded in the region of difference-1 (RD1), a
portion of Mtb genome absent among all BCG strains and most
NTM species (Rangaka et al., 2012). Currently, two commercial
systems are available: the QuantiFERON-TB Gold in-tube assay
(QFT-GIT; Cellestis, Carnegie, Australia) that also includes
a third antigen TB7.7 and measures IFN-γ using an ELISA
method; the TSPOT.TB assay (Oxford Immunotec, Abingdon,
UK) that quantitates IFN-γ-producing cells with the enzyme-
linked immunospot (ELISPOT) technique.
Compared to TST, IGRAs are as sensitive and more specific
for detecting latent tuberculosis infection (LTBI; Pai et al., 2008)
and have better correlation with gradient ofMtb exposure (Ewer
et al., 2003; Hill et al., 2005; Diel et al., 2006). However, neither
IGRAs performed on blood nor TST appear to be able to
distinguish between individuals with LTBI and active TB (ATB;
Kang et al., 2007; Pai et al., 2008). Although these tests were
primarily developed for the diagnosis of latent TB, clinicians have
also been searching for improved diagnostic tools and explored
IGRAs for the immunodiagnosis of active TB (Kang et al., 2007;
Nishimura et al., 2008; Winqvist et al., 2009). In 2010, the USA
Centers for Disease Control and Prevention (CDC) updated
their guidelines for testing for TB infection, and concluded that
IGRAs may be used instead of TST in all situations in which
CDC recommends TST as an aid to diagnosis of Mtb infection
(Mazurek et al., 2010). Recently, IGRAs have also been evaluated
for the diagnosis of active TB directly on extrasanguinous fluids
from sites of infection, including bronchoalveolar lavage fluid
(BALF; Nishimura et al., 2008; Winqvist et al., 2009), pleural
effusion (PE; Metcalfe et al., 2010) and cerebrospinal fluid (CSF;
Thomas et al., 2008).
Nevertheless, in most developing countries including China,
the clinical utilization of IGRAs is not recommended due to
insufficient evidence of their performance in high TB burden
settings (Metcalfe et al., 2011). Additionally, the high cost of QFT-
GIT and T-SPOT.TB is one of the restricting factors against their
clinical application in developing countries (Steffen et al., 2013).
More recently, a domestic IGRA named TS-SPOT (Tongsheng
Biotech, Beijing, China) was licensed by the China Food and
Drug Administration (CFDA). This test includes a third Mtb-
specific antigen Rv3615c as stimulus besides ESAT-6 and CFP10
and saves nearly half of cost compared to the two widely
used IGRAs systems mentioned above. Antigen Rv3615c (Esx-
1 substrate protein C, EspC), encoded outside RD1, is similar in
size and sequence homology to ESAT-6 and CFP10 (MacGurn
et al., 2005) and has high specificity to confer strong potential for
T-cell-based immunodiagnosis (Sidders et al., 2008; Millington
et al., 2011) and vaccine development (Kong et al., 2014; Teng
et al., 2015). Rv3615c contains broadly recognized CD4+ and
CD8+ epitopes and T-cell responses to Rv3615c are as specific for
Mtb infection as the responses to ESAT-6 andCFP10 in bothMtb-
infected humans (Millington et al., 2011) and M. bovis-infected
cattle (Sidders et al., 2008). In this study, we aimed to determine
whether inclusion of Rv3615c as an additional stimulus in the
IGRA assay improved the diagnosis efficiency on Mtb infection
comparedwith T-SPOT.TB in populations at various levels of risk
in China. We also assessed whether this newly licensed TS-SPOT
assay could be used for the diagnosis of active TB. A cheap assay
with high quality will definitely facilitate the widespread clinical
practice of IGRAs leading to the accumulation of more clinical
data and clarification of its clinical value for ATB diagnosis in
developing countries with high TB burden.
MATERIALS AND METHODS
Clinical Trial Design and Participants
In this prospective clinical study, a total of 307 participants
were recruited in Shanghai Public Health Clinical Center
(SPHCC, Shanghai, China) from January to December 2015.
Characteristics of all participants are shown in Table 1. Study
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TABLE 1 | Characteristics of different groups of subjects in the study.
Characteristics ATB patients (n = 155) NATB controls (n = 145)
PTB (n = 118) EPTB (n = 37) Non-TB (n = 90) HC (n = 55)
Age, years (mean± SD) 44.29 ± 20.29 30.24 ± 20.11 42.62 ± 22.54 28.47 ± 6.76
≤25 (n) 25 14 21 24
26–35 (n) 23 8 10 18
36–45 (n) 13 5 16 12
46–55 (n) 14 4 14 1
56–65 (n) 21 3 13 0
>65 (n) 22 3 16 0
Gender (male: female) 76: 42 19: 18 52: 38 41: 14
BCG vaccinated (%) 100 100 100 100
Diabets mellitus (n) 9 1 1 0
Liver disease (n) 5 1 0 0
Autoimmune diseases (n) 2 0 0 0
Chronic renal failure (n) 1 1 0 0
protocols were approved by the Institutional Review Board of
SPHCC, and written informed consent was obtained from all
participants. All the participants were HIV-negative and had
BCG vaccination in early childhood or during adolescence.
As for the suspected TB cases, the diagnosis of active
tuberculosis (ATB) patients was made on the basis of all
the clinical, radiological, microbiological, and pathological
information collected after recruitment and response to anti-TB
therapy for at least 3 months. ATB subjects were further classified
into cases of pulmonary tuberculosis (PTB) and extra-pulmonary
tuberculosis (EPTB) subgroups. Recruited patients were classified
as Non-TB and therefore excluded from ATB when they had an
established alternative diagnosis, which referred to lung cancer,
pneumonia, chronic bronchitis, and bronchiectasis that are easily
confused with TB. For comparison, 55 healthy individuals with
normal chest radiographs, no known history of TB infection and
no symptoms of active TB, were also recruited. Ultimately, 155
ATB including 118 PTB and 37 EPTB and 145 NATB controls
including 90 Non-TB pulmonary disease patients and 55 healthy
individuals were tested with both TS-SPOT and T-SPOT.TB
assays (Figure 1).
Ex vivo IFN-γ ELISPOT Assay
The fresh blood samples were collected before treatment or
within 7 days at the beginning of treatment from participants
and PBMCs were isolated from a whole blood sample by
centrifugation over Ficoll density gradient (TBD Science,
Tianjing, China) in a bio-safety level 3 (BSL-3) lab. Cells
were re-suspended in AIM-V medium (Gibco, ThermoFisher,
USA) and divided into two aliquots. A total of 2.5 × 105
cells/well were seeded in 96-well plates precoated with anti-
IFN-γ capture monoclonal antibody, and ex vivo ELISPOT
assays were performed according to the manufacturer’s operating
instruction. Briefly, cells were incubated for 18–20 h at 37◦C,
5% CO2 with the different Mtb-specific antigens (one peptide
pool including ESAT-6, CFP10, and Rv3615c peptides for
TS-SPOT, two separate peptide pools including ESAT-6 or CFP10
peptides for T-SPOT.TB) to stimulate IFN-γ secretion by the
effector T cells. PBMCs in medium alone or stimulated with
phytohemagglutinin (PHA) at 2.5µg/ml were used as negative or
positive controls, respectively. Biotinylated anti-IFN-γ detection
monoclonal antibody was then added for 4 h, and followed by
the addition of streptavidin-enzyme conjugate for 1 h. After
a washing step, the chromogenic substrate was added and the
individual spots were counted by use of an automated image
analysis system, ELISPOT reader (Champspot III; Sage Creation
Science, Beijing, China).
The result of TS-SPOT was considered to be positive if either
Panel Test (containing ESAT-6/CFP-10/Rv3615c peptides pool)
showed at least six spot-forming cells (SFCs) more than the
negative control when the negative control ≤5 SFCs; or if the
number of spots in Panel Test was at least double the number in
the negative control when the negative control >5 SFCs. For the
Oxford T-SPOT.TB assay, the result was positive if either of the
two panels or both of them showed at least six SFCs more than
the negative control when the negative control≤5 SFCs; or if the
number of spots in the Panel Test was at least double the number
in the negative control when the negative control>5 SFCs.
Radiographic Image Examination and
Analysis
Chest radiographs of PTB patients were reviewed by two
experienced, board-certified radiologists who were blinded to
the TS-SPOT results. Images were assessed for the presence
and distribution of parenchymal abnormalities consistent with
infiltrates and/or cavities to determine the extent and severity of
disease. Pulmonary disease was defined as severe when lesions
characterized by lobe infiltrate, pleural effusions, and cavities
involved two or more lobes in one or both lungs (Geng et al.,
2005).
Detection of Mtb DNA in Sputum by
Real-Time PCR
Mtb DNA detection was routinely performed with aliquots of
NALC-NaOH treated sputum specimens as a method to amplify
a 254-bp fragment of Mtb IS6110 gene for TB diagnosis by
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FIGURE 1 | Flowchart of the clinical validation study.
using a real-time PCR kit (Daan Biotech, Guangzhou, China)
according to the manufacturer’s instructions. The sequences
of primers and probe used are as following: 5′-CGTGAGGG
CATCGAGGTGGC-3′, 5′-GCGTAGGCGTCGGTGACAAA-3′,
and 5′-TGCTACCCACAGCCGGTTAGG-3′, respectively. The
result was expressed as log10 copies of Mtb DNA per ml of
sputum.
Statistical Analysis
The sensitivity, specificity, PPV, NPV, LR+, LR- and diagnostic
efficiency were calculated using SPSS statistical software (SPSS
Inc., Chicago, USA). Positive rates in different groups were
compared using χ2 test. P < 0.05 was considered to be
statistically significant by 95% confidence interval analysis.
Agreement between tests was assessed by estimating Cohen’s κ
coefficient, and κ ≥ 0.75 indicates excellent agreement, 0.75 > κ
≥ 0.4 indicates fair to good agreement, and κ< 0.4 indicates poor
agreement (Mantegani et al., 2006).
RESULTS
Baseline Characteristics of Study
Population
Among 307 enrolled participants, 7 were excluded from the
final analysis due to unqualified sampling, thus a total of 300
participants were successfully evaluated with both TS-SPOT and
T-SPOT.TB assays in this study. The sample population included
118 pulmonary tuberculosis (PTB) cases, 37 extra pulmonary
tuberculosis (EPTB) cases, 55 healthy controls (HC), and 90
non-TB pulmonary disease patients (Non-TB; Figure 1). Among
ATB groups, patients with both EPTB and PTB were classified
into the PTB group. The non-TB pulmonary disease patients
and health individuals served as negative controls. The baseline
characteristics of the enrolled subjects are summarized inTable 1.
The mean ages of the patients with PTB, EPTB, Non-TB and
healthy controls were 44.29 ± 20.29, 30.24 ± 20.11, 42.62 ±
22.54, and 28.47 ± 6.76, respectively. Male patients were a high
proportion in the ATB group. All the participants had been
BCG vaccinated. Diabetes was the most common underlying
co-morbidity in patients with TB, liver disease, autoimmune
diseases, and chronic renal disease followed (Table 1). For 118
PTB cases, apart from those from whom a sputum sample
could not be collected and omitting the samples that were
contaminated during culturing, 103 sputum smear and 103
bacterial culture results were available for comparison as the
“gold standard.”
Analysis of IGRAs Results Using Clinical
Diagnosis as Reference
Of the 155 clinically diagnosed ATB patients (76.13% PTB
and 23.87% EPTB), 124 and 119 cases were detected positively
by using the TS-SPOT and T-SPOT.TB, respectively, which
resulted in the diagnostic sensitivity of 80.00% (124/155) and
76.77% (119/155), respectively. Of the 145 controls including 90
Non-TB pulmonary disease patients and 55 healthy individuals,
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24 and 21 cases were detected positively by using the TS-
SPOT and T-SPOT.TB, respectively, which resulted in the
diagnostic specificity of 83.45% (121/145) and 85.52% (124/145),
respectively (Table 2). In comparison, the positive rate by smear
microscopy was 36.89% (38/103) and was 49.51% (51/103) for
bacterial culture. There was a significant difference in diagnostic
sensitivity between the bacteriological methods and these two
IGRA assays (p< 0.01).
Comparison of the Performance of
TS-SPOT and T-SPOT.TB on ATB Diagnosis
When using non-TB pulmonary disease patients and healthy
individuals as negative controls, the sensitivity and specificity
were 80.00 and 83.45% respectively for TS-SPOT, and 76.77 and
85.52% for T-SPOT.TB. There was no statistically significant
difference between of these assays in either sensitivity or
specificity (P > 0.05, chi-square test). The PPV of TS-SPOT
and T-SPOT.TB assays were 83.78 and 85.00%, respectively; the
NPV were 79.61 and 77.50%; LR+ were 4.83 and 5.30; LR- were
0.24 and 0.27, and the diagnostic efficiencies for ATB diagnosis
were 81.67 and 81.00%, respectively (Table 2). Statistical analysis
showed no significant difference between of these two IGRA
assays.
Agreement between TS-SPOT and
T-SPOT.TB Assay
For further comparison of TS-SPOT and T-SPOT.TB, the
agreement and response correlation between these two assays
were analyzed by SPSS 11.0 in the total 300 subjects.
Concordance between the assays was measured using the
Kappa index, and the correlation between TS-SPOT response
and T-SPOT.TB response was analyzed non-parametrically by
Spearman’s correlation. In the 300 subjects, TB-SPOT and T-
SPOT.TB were both positive in 137 and both negative in 149
subjects, which resulted in an excellent agreement (κ= 0.91, 95%
CI: 0.85–0.95) between these two assays (Table 3).
TABLE 2 | Comparison of TS-SPOT and T-SPOT.TB assays.
Parameter TS-SPOT T-SPOT.TB
Positive Negative Positive Negative
(n) (n) (n) (n)
ATB Patients (n = 155) 124 31 119 36
PTB (n = 118) 100 18 96 22
EPTB (n = 37) 24 13 23 14
NATB Controls (n = 145) 24 121 21 124
Non-TB (n = 90) 18 71 17 73
HC (n = 55) 6 50 4 51
Sensitivity (%) 80.00 76.77
Specificity (%) 83.45 85.52
PPV (%) 83.78 85.00
NPV (%) 79.61 77.50
LR+ 4.83 5.30
LR− 0.24 0.27
Diagnostic efficiency (%) 81.67 81.00
Among 155 active tuberculosis patients, 117 subjects were
positive by both assays, 9 had discordant results between the
two assays: 7 were TS-SPOT+/T-SPOT.TB− and 2 were TS-
SPOT−/T-SPOT.TB+ (Figure 2A). Among 145 controls, 20 were
positive by both assays, suggesting that they might be LTBI
individuals. Of 145 control subjects, 5 had discordant results
between the two assays: 4 were TS-SPOT+/T-SPOT.TB−, 1
was TS-SPOT−/T-SPOT.TB+ (Figure 2B). These data suggest
an excellent concordance between these two IGRA assays. The
sensitivity of TS-SPOT assay was a little higher than T-SPOT.TB
for diagnosis of Mtb infection including active TB and latent TB
infection, although this did not reach statistical significance for
either group.
Performance of TS-SPOT Assay for
Diagnosis of PTB Using Bacteriological
Tests as the “Gold Standard”
When the results of bacteriological tests were used as the
“gold standard” to further evaluate the performance of the
TS-SPOT assay for diagnosis of PTB cases, the SFCs in the
bacteria-positive cases were significantly higher than those in
the bacteria-negative cases (Figure 3), the sensitivity was 86.84%
(33/38) in smear-positive cases, 92.16% (47/51) in culture-
positive cases, and 94.28% (33/35) in both smear- and culture-
positive cases. These rates were significantly higher than in total
ATB cases (80% sensitivity). Additionally, TS-SPOT assay also
detected 81.54% (53/65) in smear-negative cases, 73.07% (38/52)
in culture-negative cases, and 74.46% (35/47) in both smear-
and culture- negative cases (Table 4), which was still significantly
TABLE 3 | Agreement between TS-SPOT and T-SPOT.TB assays.
TS-SPOT T-SPOT.TB Kappa value (95%)
+ − Total
+ 137 11 148 0.91
− 3 149 152 (0.85–0.95)
Total 140 160 300
FIGURE 2 | Positive detection results from the TS-SPOT and
T-SPOT.TB assays. Venn diagram represents the number of positive results
from two IGRA assays among the 155 active tuberculosis patients including
118 pulmonary TB and 37 extra-pulmonary TB cases (A) and 145 non-TB
controls including 90 non-TB pulmonary disease patients and 55 health
individuals (B). TS-SPOT and T-SPOT.TB were all negative in 29 ATB patients
and 120 non-TB control subjects.
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FIGURE 3 | IFN-γ responses in the different forms of TB by the TS-SPOT assay. Spot-forming cells (SFCs) in the different groups of ATB, NATB, PTB, and
EPTB (A), and in the different PTB subgroups (B) are shown. The number of patients (C) or SFC numbers (D) in the different forms of extra-pulmonary TB cases are
also shown. TBM, tuberculous meningitis; LNTB, lymph node tuberculosis; TBP, tuberculous peritonitis; TBPL, tuberculous pleurisy; BTB, bone tuberculosis; ITB,
intestinal tuberculosis; RTB, renal tuberculosis. *P < 0.05, **P < 0.01, when compared as indicated.
TABLE 4 | Detection of PTB cases using bacteriological methods and TS-SPOT assay.
TS-SPOT, n (%) Smear staining Bacterial culture Total smear + culture
Positive Negative Positive Negative Positive Negative
Positive 33 (86.84) 53 (81.54) 47 (92.16) 38 (73.07) 33 (94.28) 35 (74.46)
Negative 5 (13.16) 12 (18.46) 4 (7.84) 14 (26.92) 2 (5.71) 12 (25.53)
higher than detection by sputum smear (36.89%) or bacterial
culture (49.51%; Table 4).
Clinical Characteristics Associated with
False-Negative TS-SPOT Results in
AFB-Positive PTB Patients
The TS-SPOT assay gave false-negative results for 7 patients with
sputum- or culture-positive TB in which included 2 patients
with smear- and culture-positive TB. Compared to AFB-positive
patients with positive IFN-γ TS-SPOT responses, those with
false-negative TS-SPOT results were older (P < 0.01), had fewer
bacterial DNA copies in sputum specimens measured by real-
time PCR (P< 0.01), and had proportionally more severe disease
although without significant difference, as defined by image
examination (Table 5).
IFN-γ Responses in Relation to the Clinical
Manifestation of TB
It has been suggested that different forms of TB may lead to
different immune response profiles and therefore may affect
the sensitivity of IGRAs (Nishimura et al., 2008). To address
TABLE 5 | Clinical characteristics of AFB-positive patients with
false-negative TS-SPOT results.
Value for TS-SPOT result
False negative (n = 7) Positive (n = 49)




Gender (male: female) 6: 1 32: 17
Immunosuppressive drug (no.) 2 0
Image examination (no.
severe: no. mild)
6: 1 19: 30
Mtb DNA in sputum (log
copies/ml, mean ± SD)
2.93 ± 0.35** 4.68 ± 0.89
**P < 0.01, when compared with TS-SPOT positive cases in AFB-positive patients.
this question, 37 EPTB patients including various numbers of
TB meningitis (TBM), lymph node TB (LNTB), TB peritonitis
(TBP), TB pleurisy (TBPL), bone TB (BTB), intestinal TB (ITB),
and renal TB (RTB; Figure 3C), were recruited and the IFN-γ
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 6 April 2017 | Volume 7 | Article 117
Li et al. TB Diagnosis by TS-SPOT Assay
responses of patients with different forms of TB were compared.
In PBMCs from ATB patients the mean magnitude of IFN-γ
response to the mixture ofMtb-specific antigens (ESAT-6, CFP10
and Rv3615c) was significantly higher than that of PBMCs from
NATB controls (Figure 3A). Patients with extra-pulmonary TB
had lower IFN-γ responses than those with PTB (Figure 3B),
with the highest sensitivity for patients with culture-positive
pulmonary TB (47/51, 92.16%) and the lowest for those with
tuberculosis meningitis (4/8, 50.00%; Table 4). However, there
were no significant differences among the various EPTB forms
(Figure 3D). Thus, the positive rate of the TS-SPOT assay in
EPTB (24/37, 64.86%) was also lower than that in PTB (100/118,
84.75%).
DISCUSSION
IGRAs are in vitro immunologic diagnostic tests to identify Mtb
infection. Currently, two systems including QFT-GIT and T-
SPOT.TB are commercially available, and their use in clinical
practice is more and more widespread. Whereas, the IGRAs were
initially conceived to support diagnosis of latent infection, an
increasing body of evidence is published on its use in detection
of active TB infection (Kang et al., 2007; Nishimura et al., 2008;
Thomas et al., 2008; Winqvist et al., 2009; Mazurek et al., 2010;
Metcalfe et al., 2010). A significant increase in the number of
guidelines now includes recommendations for the use of IGRAs
in the differential diagnosis of active TB in low-risk TB settings
(Denkinger et al., 2011). China is one of the developing countries
with high TB prevalence and widespread BCG vaccination, and
TST detection has been demonstrated to be of poor specificity
due to the cross-reaction with BCG vaccination (Richeldi, 2006).
However, while IGRAs have been widely used to detect Mtb
infections with high specificity and sensitivity, the high risk of
Mtb infection and high cost of these assays limits their use in
clinical practice in China, especially in low-income countryside.
For the first time, a newly licensed PBMCs-based IGRA
named TS-SPOT, was used for the diagnosis of active TB, and
its performance in detection of Mtb infection was compared
to that of T-SPOT.TB as control in this study. The results
showed that the sensitivity, specificity, PPV, NPV, LR+, LR- and
diagnostic efficiency on ATB diagnosis of this new assay was
80.00, 83.45, 83.78, 83.45, 4.83, 0.24, and 81.67%, respectively,
which were all similar to the imported T-SPOT.TB assay that
had sensitivity, specificity, PPV, NPV, LR+, LR- and diagnostic
efficiency of 76.77, 85.52, 85.00, 85.51, 5.30, 0.27, and 81%,
respectively (Table 2). Consequently, there was a nearly complete
concordance with an excellent Kappa value of 0.91 between these
two PBMCs-based IGRAs, TS-SPOT and T-SPOT.TB.
In direct comparison of these two IGRA assays, TS-SPOT
detected a higher number of ATB patients than T-SPOT.TB (124
vs. 119; Table 2), indicating higher sensitivity of TS-SPOT assay
(80.00 vs. 76.77%) for diagnosis of active tuberculosis. The Venn
diagrams showed that most of the positive ATB (117/126) cases
had consistent results between these two assays. The finding
of 7 ATB cases with TS-SPOT+/T-SPOT.TB− results further
indicated that TS-SPOT assay may have a higher sensitivity for
diagnosis of active TB than T-SPOT.TB (Figure 2A), although
there were no statistical differences between them. This may be
because of inclusion of the third Mtb-specific antigen Rv3615c
as stimulus besides ESAT-6 and CFP10 in the TS-SPOT assay;
the additional positive cases may be having had unique Rv3615c-
specific responses. Similarly, TS-SPOT also showed a higher
positive rate in the NATB controls (24 vs. 21) than T-SPOT.TB
(Table 2) or 4 additional cases with TS-SPOT+/T-SPOT.TB−
results (Figure 2B). This resulted in a lower specificity (83.45
vs. 85.52%) on diagnosis of active tuberculosis when using non-
TB patients with pulmonary diseases and healthy individuals as
the control population (Table 2). Due to the high prevalence
of Mtb infection in China, it is plausible that the positive
responses of control individuals could be due to LTBI. However,
evaluating the accuracy of IGRAs in diagnosing LTBI remains
a problem since there is no “gold standard” for such diagnoses.
Actually, when analyzing the background information, we note
that all of the four additional positive subjects (TS-SPOT+/T-
SPOT.TB−) are respiratory physicians/thoracic surgeons or ATB
contacts who have no symptoms and are at high risk of infection
with tuberculosis. Accordingly, the seeming lower specificity on
diagnosis of active TB possibly reflected a higher sensitivity for
positive detection of latent TB infection. However, there were also
2 ATB and 1 NATB cases with TS-SPOT−/T-SPOT.TB+ results
which remain unexplained.
When further analyzing its performance for diagnosis of
pulmonary TB using bacteriological tests as the “gold standard,”
TS-SPOT assay showed up to 90% (80/89) agreement in the
smear-/culture-positive cases, and 77.78% (91/117) positive rate
in the smear-/culture-negative cases, which was significantly
higher than the 36.89% (38/103) by sputum smear or 49.51%
(51/103) by bacterial culture in the bacteriological tests (Table 4).
Certainly, negative results were inevitably seen in 7 patients with
sputum- and/or culture-positive TB. Nevertheless, those with
false-negative TS-SPOT results were either older or showed fewer
bacterial DNA copies compared to AFB- and TS-SPOT-positive
patients (Table 5). This was also reported previously from studies
using an in-house IFN-γ ELISPOT assay (Chen et al., 2009).
Thus, the findings indicate that TS-SPOT assay could be a useful
tool for rapid diagnosis of active tuberculosis compared to the
low-efficacy of sputum smear and time-consumption of Mtb
culture.
It should be noted that the sensitivity of IGRAs may vary
among different forms of tuberculosis. Consistent with a recent
study reporting a lower sensitivity of the T-SPOT.TB assay for
diagnosis of extra-pulmonary TB compared with PTB (Wang
et al., 2015), we also observed a lower magnitude of IFN-γ
responses in patients with extra-pulmonary TB than in those
with PTB (Figure 3A), which resulted in the higher positive rate
in PTB cases (84.75%) than in EPTB cases (64.86%; Table 2).
Our results also showed that the magnitude of IFN-γ responses
did not differ significantly between EPTB and non-TB controls
(Figure 3A) or among the various EPTB forms (Figure 3D). A
similar observation was seen in a reported study of Vietnamese
patients, which argued against the use of the IFN-γ ELISPOT
assay for diagnosis of tuberculous meningitis in blood (Simmons
et al., 2006). The low IFN-γ responses seen in patients with severe
TB reflects the complex roles of IFN-γ in immunity and the
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pathogenesis of TB and a comprehensive understanding of the
role of IFN-γ responses should lead to better clinical indications,
applications, and utilization of IFN-γ as a biomarker (Andersen
et al., 2007). Although relatively low IFN-γ responses were seen
in the patients with the EPTB forms compared to PTB cases,
the positive rate of TS-SPOT in the EPTB cases was still high,
up to 64.86% (Table 2). This was significantly higher than the
sensitivity (8/37, 21.62%) using the bacteriological tests based
on the body fluid samples (Figure 1). Thus, TS-SPOT assay
may be a useful adjunct to the current tests for rapid diagnosis
of extra-pulmonary TB. The sensitivity might be substantially
improved by using body fluid samples of EPTB cases instead of,
or in addition to, the blood-based PBMCs; Wang et al. reported
that T-SPOT.TB showed high sensitivity in the diagnosis of
tuberculous pleurisy and peritonitis (82.35 and 80%, respectively)
and high specificity (75 and 100%, respectively) when pleural
effusion and ascites fluid were used as samples (Wang et al.,
2015).
Taken together, the evidence in this current study shows
that TS-SPOT, a recently licensed IFN-γ release assay in China,
has high sensitivity and specificity in diagnosis of active TB
with essentially excellent agreement with the widely available
T-SPOT.TB assay. Additionally, it may be useful to aid in the
clinical detection and diagnosis ofMtb infection in patients with
smear- and/or culture-negative TB and extra-pulmonary TB. Due
to its cost-effective and high-quality characteristics, this assay
may be a very useful tool for TB control, especially in low-income
and high-incidence settings.
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